These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 19813338)
1. [Influence of ACE inhibitors and fibrates on endothelial function]. Januszewicz A Kardiol Pol; 2005 Jun; 62 Suppl 2():II60-4. PubMed ID: 19813338 [No Abstract] [Full Text] [Related]
2. Endothelial dysfunction and the promise of ACE inhibitors. Rockett JL Am J Nurs; 1999 Oct; 99(10):44-9; quiz 50. PubMed ID: 10542849 [No Abstract] [Full Text] [Related]
3. [Pleiotropic action of ACE-I and fibrates]. Okopień B; Haberka M; Sierant M Kardiol Pol; 2005 Jun; 62 Suppl 2():II65-8. PubMed ID: 19813339 [No Abstract] [Full Text] [Related]
4. [Drug prevention and preventive management of age related macular degeneration by positive modification of vascular endothelial dysfunction]. Fischer T Klin Monbl Augenheilkd; 2004 Dec; 221(12):1062. PubMed ID: 15599815 [No Abstract] [Full Text] [Related]
5. [Paralipomena as a reason for publication]. Fischer T Klin Monbl Augenheilkd; 2006 Feb; 223(2):178-9. PubMed ID: 16485234 [No Abstract] [Full Text] [Related]
6. Fibrate therapy: safety considerations. Usman M; Peter R Curr Opin Lipidol; 2007 Dec; 18(6):702-4. PubMed ID: 17993818 [No Abstract] [Full Text] [Related]
15. Cardiovascular benefit of cholesterol-lowering therapy: does improved endothelial vasodilator function matter? Cannon RO Circulation; 2000 Aug; 102(8):820-2. PubMed ID: 10952945 [No Abstract] [Full Text] [Related]
16. [Endothelium--a new target for a therapeutic action of angiotensin-converting enzyme inhibitors]. Karpov IuA Ter Arkh; 2004; 76(6):94-6. PubMed ID: 15332589 [No Abstract] [Full Text] [Related]
17. Key developments in cardiovascular medicine. Appleby MA; Hall A Practitioner; 2002 Jun; 246(1635):375-7, 380-2. PubMed ID: 12073696 [No Abstract] [Full Text] [Related]
18. [New perspectives for patients at risk for atherosclerosis. The importance of ACE inhibitors in cardiovascular prevention]. Landgraf W; Klein HH Pharm Unserer Zeit; 2003; 32(1):36-44. PubMed ID: 12577759 [No Abstract] [Full Text] [Related]
19. Cardioprotective properties of fibrates: which fibrate, which patients, what mechanism? Barter PJ; Rye KA Circulation; 2006 Mar; 113(12):1553-5. PubMed ID: 16567579 [No Abstract] [Full Text] [Related]
20. [No advantage of the combination of ACE-inhibition and angiotensin receptor blockade in patients with high cardiovascular risk]. Slagman MC; Waanders F; Navis GJ Ned Tijdschr Geneeskd; 2008 Sep; 152(39):2150-1; author reply 2151. PubMed ID: 18924267 [No Abstract] [Full Text] [Related] [Next] [New Search]